<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39399164</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>A Dynamic, D-dimer-based Thromboprophylaxis Strategy in Patients with COVID-19.</ArticleTitle><Pagination><StartPage>887</StartPage><MedlinePgn>887</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">887</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.146710.2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">COVID-19 pandemics increases venous thromboembolism (VTE) risk during hospitalization, despite prophylactic anticoagulation. Limited radiological diagnosis in pandemic requires a guided protocol for anticoagulant adjustment.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This retrospective cohort study was conducted at a single center as part of a quality improvement program evaluating the efficacy and safety of anticoagulation protocols. The study focused on implementing a guideline for anticoagulant dosing protocol based on dynamic changes in D-dimer levels in COVID-19 hospitalized patients. The dosing guideline allowed for dose escalation from standard prophylactic levels to escalated prophylactic or therapeutic levels, depending on the patient's risk profile for VTE. The primary endpoints included in-hospital survival comparing between fix and dynamic adjustment treatment groups. Secondary endpoints encompassed major and clinically relevant non-major bleeding (CRNMB) events, incidence of breakthrough thrombosis, length of hospitalization and ICU stay, days of mechanical ventilator use, and survival duration.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Among the 260 COVID-19-infected patients hospitalized between March 15th and June 15th, 2020. The patients received fixed anticoagulant dosage in 188, 72.3%) patients, while 72 (27.7%) were up-titrated according to the protocol. In-hospital survival at 30 days demonstrated superiority among patients whose anticoagulation was up-titrated to either escalated prophylactic or therapeutic (80.2%) compared to receiving fixed anticoagulant dosage (51.3%) (p=0.01). Bleeding events were significantly higher in up-titrate group (12.5%) compared to fixed anticoagulant dosage group (2.13%). Most of them are CRNMB.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">A dynamic, D-dimer-based dose escalation of anticoagulation for hospitalized patients with COVID-19 holds promise in improving in-hospital mortality rates without a significant increase in fatal bleeding events.</AbstractText><CopyrightInformation>Copyright: Â© 2024 Bhoopat L et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhoopat</LastName><ForeName>Lantarima</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Thammasat University, Pathum Thani, Pathum Thani, 12120, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martynova</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>April</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, University of California Irvine, Orange, California, 92868, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattharanitima</LastName><ForeName>Pattharawin</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Thammasat University, Pathum Thani, Pathum Thani, 12120, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Semi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Senxi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syed</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Los Angeles County + University of Southern California Medical Center, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Esther E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Los Angeles County + University of Southern California Medical Center, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borok</LastName><ForeName>Zea</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of California San Diego, San Diego, California, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebler</LastName><ForeName>Janice</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Melissa Lee</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences &amp; SC-CTSI, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tantiyavarong</LastName><ForeName>Pichaya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Thammasat University, Pathum Thani, Pathum Thani, 12120, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connell</LastName><ForeName>Casey O</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, 90089, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="Y">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">D-dimer</Keyword><Keyword MajorTopicYN="N">Thromboprophylaxis</Keyword></KeywordList><CoiStatement>Competing interests: Declaration of interests â The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. âThe authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Casey OâConnell: consulting fee from AbbVie Inc. Advisory Board Janice Liebler: Grants or contracts from Immunexpress, St. Michaels Hospital, Toronto, Canada, CDC Foundation No conflict of interest for other authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399164</ArticleId><ArticleId IdType="pmc">PMC11467651</ArticleId><ArticleId IdType="doi">10.12688/f1000research.146710.2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rapkiewicz AV, Mai X, Carsons SE, et al. : Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine. 2020;24:100434. 10.1016/j.eclinm.2020.100434</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100434</ArticleId><ArticleId IdType="pmc">PMC7316051</ArticleId><ArticleId IdType="pubmed">32766543</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054â1062. 10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Bai H, Chen X, et al. : Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094â1099. 10.1111/jth.14817</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14817</ArticleId><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Kruip M, Meer NJM, et al. : Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020;191:145â147. 10.1016/j.thromres.2020.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.013</ArticleId><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Tacquard C, Severac F, et al. : High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089â1098. 10.1007/s00134-020-06062-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06062-x</ArticleId><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler PR, Goligher EC, Berger JS, et al. : Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N. Engl. J. Med. 2021;385(9):790â802. 10.1056/NEJMoa2105911</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Gul MH, Htun ZM, Jesus PV, et al. : Predictors and outcomes of acute pulmonary embolism in COVID-19; insights from US National COVID cohort collaborative. Respir. Res. 2023;24(1):59. 10.1186/s12931-023-02369-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-023-02369-7</ArticleId><ArticleId IdType="pmc">PMC9942071</ArticleId><ArticleId IdType="pubmed">36810085</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeem I, Anwar A, Jordon L, et al. : Relationship of D-dimer and prediction of pulmonary embolism in hospitalized COVID-19 patients: a multicenter study. Future Microbiol. 2021;16(12):863â870. 10.2217/fmb-2021-0082</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2021-0082</ArticleId><ArticleId IdType="pmc">PMC8317973</ArticleId><ArticleId IdType="pubmed">34319144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwee RM, Adams HJA, Kwee TC: Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis. Eur. Radiol. 2021;31(11):8168â8186. 10.1007/s00330-021-08003-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-021-08003-8</ArticleId><ArticleId IdType="pmc">PMC8106765</ArticleId><ArticleId IdType="pubmed">33966132</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Nisio MD, Levy JH, et al. : New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. 10.1136/bmjopen-2017-017046</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-017046</ArticleId><ArticleId IdType="pmc">PMC5623518</ArticleId><ArticleId IdType="pubmed">28963294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaatz S, Ahmad D, Spyropoulos AC, et al. : Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J. Thromb. Haemost. 2015;13(11):2119â2126. 10.1111/jth.13140</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13140</ArticleId><ArticleId IdType="pubmed">26764429</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher EC, Bradbury CA, McVerry BJ, et al. : Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N. Engl. J. Med. 2021;385(9):777â789. 10.1056/NEJMoa2103417</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103417</ArticleId><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Demelo-RodrÃ­guez P, Cervilla-MuÃ±oz E, Ordieres-Ortega L, et al. : Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb. Res. 2020;192:23â26. 10.1016/j.thromres.2020.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.05.018</ArticleId><ArticleId IdType="pmc">PMC7219400</ArticleId><ArticleId IdType="pubmed">32405101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhoopat L: A Dynamic, D-dimer-based Thromboprophylaxis Strategy in Patients with COVID-19.[Data set]. Zenodo. 2024. 10.5281/zenodo.12687462</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.12687462</ArticleId><ArticleId IdType="pmc">PMC11467651</ArticleId><ArticleId IdType="pubmed">39399164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhoopat L: STROBE checklist for A Dynamic, D-dimer-based Thromboprophylaxis Strategy in Patients with COVID-19. Zenodo. 2024. 10.5281/zenodo.12730540</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.12730540</ArticleId><ArticleId IdType="pmc">PMC11467651</ArticleId><ArticleId IdType="pubmed">39399164</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>